Interpace Biosciences (IDXG) Proxy filing summary

Executive summary

• Annual meeting scheduled for August 20, 2026, with virtual participation available.

• Shareholders are invited to vote on key proposals, including board structure, equity plans, and auditor ratification.

Voting matters and shareholder proposals

• Proposal to amend and restate the Certificate of Incorporation, increasing authorized shares to 200,000,000, introducing blank check preferred stock, and declassifying the board for annual director elections.

• Proposal for a reverse stock split at a ratio between 1-for-2 and 1-for-10, at the board's discretion.

• Approval sought for the 2026 Equity Incentive Plan and 2026 Employee Stock Purchase Plan.

• Advisory vote on executive compensation and ratification of EisnerAmper, LLP as independent auditor for 2026.

Board of directors and corporate governance

• Election of five director nominees if Proposal 1 passes; otherwise, staggered election of Class I and Class III directors for terms ending 2028 and 2029, respectively.

• Board recommends voting in favor of all director nominees and governance changes.